Target Entity

Ayugenomics Private Limited

Type of Deal

Acquisition (majority stake) through incorporation of a new subsidiary company.

Stake/Capacity

The Company shall hold 60% of the equity share capital of Ayugenomics Private Limited, comprising 30,000 equity shares of ₹10 each out of a total authorized share capital of ₹5,00,000 divided into 50,000 equity shares.

Deal Value

₹3,00,000, comprising subscription to 30,000 equity shares of ₹10 each.

Funding Source

Cash consideration through banking channels.

Financial Impact

Not disclosed regarding revenue contribution, EBITDA impact, or synergy expectations. The subsidiary is newly incorporated and has not commenced business operations.

Timeline

The acquisition was completed on the date of incorporation: 11th November, 2026.

Strategic Rationale

To carry on the business of research, development, testing, diagnostics and clinical services that combine genomics and allied omics sciences with Ayurveda and other AYUSH systems of medicine. This includes developing genomics-based panels, tests and software, clinical decision-support and artificial intelligence platforms, and clinical databases and registries. It also includes conducting clinical studies and evidence-generation programmes; developing, validating, manufacturing, licensing and commercialising evidence-based herbal nutraceutical and botanical products and treatment protocols; and offering wellness, preventive-health, training and certification programmes. The company will work with hospitals, government and state programmes and national and international institutions, including in Japan and other overseas markets. It will seek patents, regulatory approvals and registrations in India and abroad, including CDSCO and the US FDA, and will own and commercialise the intellectual property created by the company.

Approval Status

Board-approved. The incorporation was done pursuant to an earlier Board-approved proposal. No specific governmental or regulatory approvals were identified as presently required for the incorporation.

Reference Regulation

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30 read with Part A of Schedule III and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Additional Details

  • CIN of Subsidiary: U72100DC2026PTC476416
  • Country of Incorporation: India
  • Related Party Transaction: Ayugenomics Private Limited is a subsidiary of Jeena Sikho Lifecare Limited and constitutes a related party. Mr. Manish Grover, Promoter and Managing Director of Jeena Sikho Lifecare Limited, is also a Director of Ayugenomics Private Limited.
  • Transaction Basis: The shares were subscribed at an "arm's length" price i.e., face value.